Cabazitaxel

BNF:

8.1

Status:

Red

Decision Date:

September 2016

Comments

RED: 

• NICE TA391: for the treatment of hormone-relapsed, metastatic prostate cancer treated with docetaxel.

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again